3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
4
Depression
4
Head and Neck Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Fatigue
2
Anxiety Disorders
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Sleep Wake Disorders
1
Recurrence
1
Radiation Fibrosis Syndrome
1
Prostatic Neoplasms
1
Prostatic Hyperplasia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Patient Acceptance of Health Care
1
Pain
1
Neoplasm Metastasis
1
Myasthenia Gravis
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Calculi
1
Inflammatory Breast Neoplasms
1
Immune Checkpoint Inhibitor-Induced Dermatitis
1
Health Education
1
Constriction, Pathologic
1
Interventions
Magnetic Resonance Spectroscopy
49
enzalutamide
46
apalutamide
36
Specimen Handling
34
Androgen Antagonists
30
Abiraterone Acetate
29
Radiosurgery
27
Prednisone
26
darolutamide
25
Docetaxel
23
Pluvicto
22
abiraterone
20
Radiotherapy
19
Biopsy
17
Leuprolide
15
relugolix
11
gallium 68 PSMA-11
11
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
Surveys and Questionnaires
11
Radiation
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
11
Standard of Care
10
Nivolumab
10
cabazitaxel
9
X-Rays
9
Triptorelin Pamoate
9
bicalutamide
8
Carboplatin
8
pembrolizumab
7
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Therapeutics
×
90 days
×
Clear all
NCT07581184
2026-05-12
BActinium-1
Aktis Oncology, Inc.
Phase 1
Recruiting
138 enrolled